Hoffman M, Autor A P
Biochem Pharmacol. 1982 Mar 1;31(5):775-80. doi: 10.1016/0006-2952(82)90462-2.
Oxygen consumption and superoxide anion production by pulmonary macrophages are both increased by phorbol myristate acetate (PMA) but the two processes have been separated using protease inhibitors and cyclooxygenase inhibitors. Pretreatment with the protease inhibitors (L-1-tosylamido-2-phenylethylchloromethyl ketone (TPCK) and N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK), as well as with the cyclooxygenase inhibitors acetylsalicylic acid (ASA) and ibuprofen (IBU), inhibited the stimulation of superoxide production and oxygen consumption by phorbol myristate acetate. However, whereas the order of potency for inhibition of stimulation of superoxide production was TPCK greater than TLCK greater than IBU greater than ASA, the order of potency for inhibition of stimulation of oxygen consumption was ASA greater than IBU greater than TPCK = TLCK. Although all four agents were effective inhibitors of PMA-stimulated superoxide production and oxygen consumption when added before PMA, in contrast to the cyclooxygenase inhibitors. TPCK was unable to inhibit oxygen consumption by more than 70-80% regardless of the concentration used, although superoxide generation could be inhibited completely. When added after PMA, ASA did not suppress either oxygen consumption or superoxide production and ibuprofen was only one-half as effective as an inhibitor. TPCK and TLCK, when added after PMA, accelerated the return to basal rates of both oxygen consumption and superoxide production. None of the four agents had any effect on basal superoxide production or oxygen consumption at the concentrations used. The data support the interpretation that both prostaglandin biosynthesis and protease activity may be associated with the activation of the superoxide-generating system of pulmonary macrophages. The consumption of molecular oxygen following stimulation of the cells with phorbol myristate acetate is not due solely to the generation of superoxide, however, since each process is inhibited with different potency by the same group of inhibitors. There appears to be a component of oxygen consumption which results from the activation of cyclooxygenase and, unlike superoxide production, cannot be completely inhibited by treatment with protease inhibitors.
佛波醇肉豆蔻酸酯(PMA)可增加肺巨噬细胞的耗氧量和超氧阴离子生成量,但利用蛋白酶抑制剂和环氧化酶抑制剂已将这两个过程区分开来。用蛋白酶抑制剂(L-1-甲苯磺酰氨基-2-苯乙基氯甲基酮(TPCK)和N-α-对甲苯磺酰-L-赖氨酸氯甲基酮(TLCK))以及环氧化酶抑制剂乙酰水杨酸(ASA)和布洛芬(IBU)进行预处理,可抑制佛波醇肉豆蔻酸酯对超氧生成和耗氧量的刺激。然而,虽然抑制超氧生成刺激的效力顺序为TPCK>TLCK>IBU>ASA,但抑制耗氧量刺激的效力顺序为ASA>IBU>TPCK = TLCK。尽管在PMA之前添加时,所有这四种试剂都是PMA刺激的超氧生成和耗氧量的有效抑制剂,但与环氧化酶抑制剂不同。无论使用何种浓度,TPCK都无法将耗氧量抑制超过70 - 80%,尽管超氧生成可被完全抑制。在PMA之后添加时,ASA既不抑制耗氧量也不抑制超氧生成,而布洛芬作为抑制剂的效果只有一半。TPCK和TLCK在PMA之后添加时,加速了耗氧量和超氧生成量恢复到基础速率。在所使用的浓度下,这四种试剂对基础超氧生成或耗氧量均无任何影响。这些数据支持这样一种解释,即前列腺素生物合成和蛋白酶活性可能都与肺巨噬细胞超氧生成系统的激活有关。然而,用佛波醇肉豆蔻酸酯刺激细胞后分子氧的消耗并非仅由超氧生成所致,因为同一组抑制剂对这两个过程的抑制效力不同。似乎存在一部分耗氧量是由环氧化酶的激活引起的,并且与超氧生成不同,用蛋白酶抑制剂处理不能完全抑制它。